Assessment of survival without cardiac disease of thalassemic patients of Shiraz, Iran, 2005

H Ansari; hamid reza tabatabaee

Zahedan Journal of Research in Medical Sciences

The Official Journal of Zahedan University of Medical Sciences

Current Issue All Issues In Press Articles Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Assessment of survival without cardiac disease of thalassemic patients of Shiraz, Iran, 2005

Author(s):

H Ansari^1,*,

hamid reza tabatabaee²

1Public Health Dept, Faculty of Health, Zahedan University of Medical Sciences and health services, Zahedan, Iran.

2Instructor, Epidemiology and Statistic dept, Faculty of Health, Shiraz University of Medical Science and health services, Shiraz, Iran.

Zahedan Journal of Research in Medical Sciences:Vol. 8, issue 1; e94917

Published online:Mar 21, 2006

Article type:Research Article

Received:Feb 10, 2005

Accepted:Mar 16, 2006

How to Cite:H Ansarihamid reza tabatabaeeAssessment of survival without cardiac disease of thalassemic patients of Shiraz, Iran, 2005.Zahedan J Res Med Sci.8(1):e94917.

Abstract

Background: Thalassemia is the most common hemolytic anemia in the world. Absence or
irregular chelation therapy in these patients leads to cardiac complications such as heart failure,
precarditis and arrhythmia. These complications are among the most common cause of death in
thalassemic patients. The purpose of this study was investigation of survival without cardiac
disease and effective factors in these patients.
Methods and materials: In a retrospective study (with enumeration method) the survival without
cardiac disease was studied in 806 thalassemic patients (406 male and 400 female) referring to
Cooley’s ward of Dastgheib hospital in Shiraz using a data collection form. In addition to
determination of age of cardiac disease incidence to survival analysis, demographic information
and age at onset and type of transfusion and age at onset and method of chelation therapy also
specified. Our data analyzed using descriptive and analytical (Kaplan-Meier and Log Rank test)
statistic.
Results: The age range of the subjects was from 1 to 43 years (mean ± SD: 15.34 years ± 6.82).
The prevalence of cardiac disease was 15.9%. The mean age of onset of cardiac disease and mean
age of patients with complications were 16.93 ± 5.44 and 19.6 ± 5.8 respectively and the estimated
average years of survival with cardiac disease was 2.67 years. The median of survival without
cardiac disease was 31.5 years and the estimated rates of survival without cardiac disease of 20
and 25 years were 75% and 69% respectively. There was a significant association between
cumulative probability of occurrence of cardiac disease and age, education of parents and age of
chelation therapy onset.
Conclusions: Early onset of blood transfusion with late onset of chelating therapy increases the
occurrence probability of cardiac disease. Educational level of parents and education of parents
and patients about thalassemia and its complication would be very helpful in prevention of
complications.

Keywords

Fulltext

The full text of this article is available on the PDF file.

References

1.
The References of this article are available on the PDF file.

comments